China Grants Breakthrough Therapy Designation to Innovent’s IBI363 for Hard-to-Treat Melanoma

Innovent Biologics, Inc.  a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...

March 31, 2025 | Monday | News
FDA Approves CABOMETYX® for Treatment of Advanced Neuroendocrine Tumors in Adults and Pediatric Patients

 Exelixis, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the tre...

March 28, 2025 | Friday | News
Merck Reports Positive Phase 3 Results for Subcutaneous Pembrolizumab in Metastatic NSCLC

Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...

March 28, 2025 | Friday | News
Candel Therapeutics Reports Promising Survival Data for CAN-2409 in Stage III/IV NSCLC Patients Resistant to ICI Treatment

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight ca...

March 27, 2025 | Thursday | News
Junshi Biosciences' Toripalimab (LOQTORZI®) Approved in Singapore for First-Line Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 27, 2025 | Thursday | News
New Data at ELCC 2025 Reinforces Tagrisso's Role in Treating EGFR-Mutated Lung Cancer Across Stages

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso...

March 26, 2025 | Wednesday | Reports
CG Oncology Reports 75.5% Complete Response Rate in Phase 3 Bladder Cancer Study

CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-...

March 25, 2025 | Tuesday | Reports
Actinium Pharma Signs Actinium-225 Supply Deal with Eckert & Ziegler

Actinium Pharmaceuticals, Inc.(Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it has entered into an agreemen...

March 25, 2025 | Tuesday | News
CStone Pharmaceuticals Submits EMA Application for Sugemalimab to Treat Unresectable Stage III NSCLC

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...

March 24, 2025 | Monday | News
Shanghai Junshi Biosciences' Toripalimab Receives NMPA Approval for First-Line Treatment of Metastatic Liver Cancer

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 24, 2025 | Monday | News
Menarini Group and Stemline Collaborate with VisualDx to Enhance Early Detection of BPDCN Using AI/ML Technology

Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...

March 24, 2025 | Monday | News
Rhythm Pharmaceuticals Receives Orphan Drug Designation for Setmelanotide in Japan for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendoc...

March 21, 2025 | Friday | News
Whitehawk Therapeutics Debuts New Identity, Advances ADC Portfolio

Whitehawk Therapeutics, Inc. formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to establis...

March 19, 2025 | Wednesday | News
Innovent & HUTCHMED Report Positive FRUSICA-2 Trial Results for Advanced RCC

 Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treat...

March 19, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close